<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03539887</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-0903</org_study_id>
    <nct_id>NCT03539887</nct_id>
  </id_info>
  <brief_title>Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to evaluate the potential rapid and sustained antisuicidal and
      antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood
      episode in Major Depressive Disorder (MDD) or Bipolar Disorder (BD) with or without comorbid
      recent abuse of alcohol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinicians have a limited ability to predict imminent suicidal behavior and efficacious
      treatments are not available to treat suicidal patients. Thus, Rapid-acting treatments for
      suicidal individuals are truly needed. This project aims to evaluate the potential rapid and
      sustained antisuicidal and antidepressant effects of a single intranasal dose of ketamine in
      inpatients during a mood episode (in Major Depressive Disorder, MDD or Bipolar Disorder, BD)
      with or without comorbid recent abuse of alcohol. These results will elucidate the
      antisuicidal effects of ketamine using the intranasal route along with the identification of
      associated mediators or moderators; this approach has the potential for enormous public
      health impact.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Suicidal ideation as assessed by the Scale for Suicide Ideation (SSI)</measure>
    <time_frame>24 hours</time_frame>
    <description>The scale contains 19 items rated on a scale from 0 to 2, allowing score range from 0 to 38, score over 4 (first five items) will be considered inclusion criteria. Higher values indicate worsening or presence of suicidal ideation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>24 hours</time_frame>
    <description>It has ten items, each item yields a score of 0 to 6. Hence the overall score ranges from 0 to 60. Higher scores indicate more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snaith-Hamilton Pleasure Scale</measure>
    <time_frame>4 and 24 hours</time_frame>
    <description>The Snaith-Hamilton Pleasure Scale (SHAPS) is an assessment of anhedonia, which has been extensively used by our group. The 14-item measure takes 5 minutes to complete (Snaith et al 1995).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol Urge Questionnaire (AUQ)</measure>
    <time_frame>4 and 24hs</time_frame>
    <description>Alcohol Urge Questionnaire (AUQ) is a multi-item measure of self- reported urges to drink alcohol, predictor of drinking abuse and relapse (Bohn MJ, Krahn DD, Staehler BA 1995) and AUDIT/CIWA.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Suicidal Ideation</condition>
  <condition>Depression</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Intranasal ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal ketamine in alcohol abuse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>non-active placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in alcohol abuse</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>non-active placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal ketamine</intervention_name>
    <description>Intranasal ketamine will be prepared as 100mg/ml ketamine in 0.9% saline. An mucosal atomization device will be used to provide 5 intranasal applications of solution (volume 100 μl), separated by 3 minutes, over a total of 15 minutes. Each of five ketamine applications will provide 10 mg of study drug, for a total of 50mg. The dose to be used (0.5-1mg/Kg) is 6 to 18 times lower than the sedation dose (6-9mg/Kg).</description>
    <arm_group_label>Intranasal ketamine</arm_group_label>
    <arm_group_label>Intranasal ketamine in alcohol abuse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline alone. An mucosal atomization device will be used to provide 5 intranasal applications of saline (volume 100 μl), separated by 3 minutes, over a total of 15 minutes.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo in alcohol abuse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary admission to Harris County Psychiatry Center

          -  Able to provide written informed consent

          -  Current suicidal ideation and depressive symptoms and Diagnostic and Statistical
             Manual of Mental Disorders -IV- Text Revision(DSM-IV-TR) depressive episode (also
             MADRS greater than or equal to 12) and Young Mania Rating Scale (YMRS) score lower
             than 8

          -  DSM-IV-TR criteria for current alcohol abuse (but not intoxicated/withdrawal,
             abstinent from drinking for &gt; 5 days prior to admission).

          -  Lifetime history of suicide attempt (patient)

          -  Not taking any medication in the last 24hs.

          -  SSI score over 4 (first five items) and Columbia scale (C-SSRS) score 4 or 5

        Exclusion Criteria:

          -  Unstable medical condition or medical problem with known central nervous system (CNS)
             effects, e.g. uncontrolled hypertension systolic blood pressure (SBP) ≥170 and/or
             diasotlic blood pressure (DBP) ≥100) or recent history (6 months) of
             alcohol-withdrawal seizures or significant abnormal laboratory tests (liver function
             test (LFT) 3 times higher than normal).

          -  Prior diagnosis of a DSM-IV-TR psychotic spectrum disorder, psychotic symptoms, or
             personality disorder.

          -  Currently under the acute effects of an illicit substance.

          -  Pregnant or nursing women.

          -  Subjects with a history of DSM-IV drug dependency or abuse (except for caffeine or
             nicotine dependence) within the preceding 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Machado-Vieira, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodrigo Machado-Vieira, MD, PhD, MSc</last_name>
    <phone>(713) 741-6047</phone>
    <email>Rodrigo.MachadoVieira@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah H Hernandez</last_name>
    <phone>713-741-6087</phone>
    <email>Sarah.K.Hernandez@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Machado-Vieira, MD PhD MSc(713) 741-3830</last_name>
      <phone>(713) 741-3830</phone>
      <email>Rodrigo.MachadoVieira@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://med.uth.edu/psychiatry/faculty/rodrigo-machado-vieira-m-d-ph-d-m-sc/</url>
    <description>Department of Psychiatry, Dr Rodrigo Machado-Vieira</description>
  </link>
  <link>
    <url>https://med.uth.edu/psychiatry/research/programs/experimental-therapeutics-molecular-pathophysiology-program/</url>
    <description>Experimental Therapeutics and Molecular Pathophysiology, UTHealth, Houston, Texas</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2018</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Rodrigo Machado-Vieira, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Depression</keyword>
  <keyword>Suicidal Ideation</keyword>
  <keyword>Alcohol Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

